One for the watch lists.
UPLD made a hard move from ~2.75 on Friday to close ~3.35 then went on in after hours to close at a high of nearly 4.00. No news that I could find preceded this but they do have some significant headlines pending.

Additionally, the 4.00 level is meaningful resistance, and if it decisively breaks it could go hard. A quick look at the chart over the last quarter will show some pretty incredible levels. You can see those for yourselves, but I'll keep my quotes conservatively tethered to earth and just say I don't see any meaningful resistance again until 5.00.

To me, that makes it worth watching, so I'll drop a little bit of background info here. I'm by no means an expert so if this piques your interest by all means fill in any blanks I've left and share your DD here.

I trade pennies so the first thing I want to look at is their "relative" financial health and cross-reference that with their capacity of dilution. Note, these are pennies and I'm not looking for a ten-year cash runway with no debt. I say "relative" financial health because what concerns me most is their current financing need and whether that points to dilutive intent in the next few months.

They look to be in a "safe window" with about the lowest threat-score you can hope for in small caps. I've attached a snippet of the positive highlights from recent ER. Moreover, I've attached a dilution analysis from thescanner.ai which, IME, gives the most bulletproof snapshot available on public platforms, and I say that as someone who has subscribed to both dilutiontracker.com as well as AE. These two should be attached images 2 and 3. Finally, they appear to have positive cash flow and meaningful cash flow at that, ticking a little over 5M per quarter.

The next thing I want to see are current or pending catalysts. The CEO sent a pretty interesting shareholder letter on July 28th that was strategically bullish and pointed to some genuinely attractive catalyst possibilities. He describes a deliberate pivot to focusing on the monetization of the customers, infrastructure, and enterprise relationships the company excels with already. Read the letter.

What really jumps out from a strategic standpoint is probably the existing customer base of over 1,100 enterprise clients. A sample of their current partners is uploaded here as image 4. Upland already has software integrated into complex enterprise workflows. Replacing that software can be costly, disruptive, and time-consuming.

Now consider what happens when Upland introduces AI capabilities that make those same workflows significantly more valuable. This means higher revenue through upselling, better retention, and higher operating margins. It's also worth noting the CEO made a very tangible and measurable productivity claim that customers can produce content 85% faster using its AI-enhanced technology.

You can see immediately following this letter that the stock price moves well on news, especially evidenced by an 8/6 PR that moved from ~4.00 to 5.30 which sustained and expanded over the following days to a high of ~6.40 before losing steam. Notably, this move also began before the actual PR.

Taken together, these dynamics create a landscape rich in potential headlines for UPLD. The highest potential rests on announcements of AI existing contract expansions. I'm looking for meaningful upsells to existing enterprise customers, especially with contract values or recurring revenue disclosed. Here is the highest probability source of tradable news.

Their new strategy emphasizes maximization of current relationships in their current wheelhouse but it doesn't preclude new partnerships. I think the stock price could go absolutely crazy if they announce a new enterprise AI customer win.

Even public-sector wins can move the price so long that they are financially meaningful.

Secondary to these, a more predictable catalyst could come in the form of 3Q earnings and guidance. We've seen great transparency around the strategic pivot and we've seen meaningful follow-through thus far. Q2 showed 81 new customers and 200 existing customer expansions. If they are able to show meaningful AI revenue, stronger cash flow, or if guidance exceeds expectations, they are in a position to undergo a major repricing event by year's-end.

Note, the earnings catalyst is a bit off topic as it almost certainly doesn't have anything to do with this most recent activity on Friday. Just including it as a heads-up for a catalyst for which we wil have a bit of lead-time to prepare for.

This is a lot of info and I hope it helps. Please feel free to jump in and round it out with any additional DD you feel is important.

Thanks all and happy trading.

PNXP d/b/a T-MINES just opened TMINES.COM to mining operators worldwide.
Concessions, producing mines, and future production can now onboard with independent verification and raise on a compliance-first rail. Initial focus: Colombian gold.
Pending name change to Tokenization Mines Corp. Real assets, tokenized

T-MINES Opens to Mining Operators

Nice volume on these two

Sekur Private Data (OTCQB: SWISF) has launched a Portuguese-language version of Sekur.com as it prepares to expand in Angola. The company has also begun adapting its onboarding and workflows for local partners. This is a practical step in a broader plan: make its secure communications products easier to introduce, sell and deploy in a market where it expects to sign an exclusive partnership in the coming weeks.

• SWISF closed at US$0.0242 on September 25, putting its market value near US$6.3 million based on 259.6 million shares outstanding at June 30.
• Sekur’s Portuguese site is live, and the company is preparing local onboarding ahead of a prospective exclusive partnership in Angola.
• At US$300 per month for SekurOne, a relatively small premium customer base could have a meaningful effect on Sekur’s revenue and create room for SWISF to re-rate.

Building a local route to customers

For an international technology company, language is part of the sales process. Government and enterprise buyers need to review a product, enroll users and manage support in a way their teams can use every day. Sekur’s September 22 announcement says the Portuguese website is available now, while translation of workflows and onboarding has begun. The site gives prospective customers and partners a direct introduction to Sekur’s products in Angola’s official language.

That work could become valuable beyond one country. Sekur specifically identified Mozambique as another Portuguese-speaking market that the localized platform could serve. Each new market would require its own distribution and customer wins, but reusable language and onboarding tools could make the next launch more efficient. The company already operates a Spanish-language site, showing how its international sales materials can be adapted market by market.

The products have a clear intended audience. Sekur offers Swiss-hosted encrypted email, messaging and VPN services alongside SekurOne, its integrated voice and communications platform. It markets these tools to government, defense, enterprise and executive users who want greater control over sensitive communications. The company also offers deployment options aimed at organizations with data sovereignty requirements. In Angola, a local partner could connect that product suite with buyers that Sekur would find difficult to reach through its website alone.

Angola could open more than one sales channel

Sekur’s September 1 shareholder letter described discussions about a possible nationwide exclusive partnership in Angola. Its September 22 release says an exclusive agreement is expected in the coming weeks. The proposed partnership has not yet been announced as signed, and its commercial terms have not been disclosed. A signed agreement identifying the partner and its responsibilities would be an important next milestone.

The potential customer base extends beyond one type of buyer. A partner with relationships in government, telecommunications or large enterprises could introduce Sekur’s tools to teams that need secure email, private messaging or encrypted calls. An initial deployment could give Sekur local user feedback and a reference for further sales. If the relationship works, a single distribution channel may support multiple products and recurring subscriptions over time.

There is regional optionality, too. Sekur has reported interest in the Democratic Republic of Congo, where it said a government security body had given its solution a positive recommendation. That is an early stage development, not a paid order. Together with the Portuguese launch, it shows a company assembling several routes into African markets.

Premium subscriptions could change the revenue picture

The timing of the Angola push matters because SekurOne is nearing its planned commercial launch. Management expects iOS and web availability in early October at US$300 per user per month, followed by Android in November and video conferencing by year-end. In the same shareholder update, management estimated that approximately 200 SekurOne subscribers, generating US$60,000 in gross monthly recurring revenue, could bring the company to profitability.

Here is the arithmetic at the stated list price across SekurOne markets:

These are full-year, full-price examples, not an Angola sales forecast or announced contracts. Enterprise pricing, distributor terms and customer retention will determine the revenue Sekur actually earns. The sensitivity is useful because the company’s reported first-half 2026 revenue was C$185,828. A few hundred premium subscribers, whether won in the United States, Angola or other markets, would represent a substantial addition to its current sales base.

What the opportunity could mean for SWISF

SWISF’s small valuation makes commercial progress especially relevant. Using the September 25 US$0.0242 close and June’s 259.6 million shares outstanding gives an equity value of about US$6.3 million. If Sekur eventually reached 1,000 full-price SekurOne users, the illustrative gross annual recurring revenue would be US$3.6 million. Applying a hypothetical four-times multiple to that revenue would imply US$14.4 million of equity value, or roughly US$0.055 per share on the June share count. That is about 129% above the reference price. This is an illustrative calculation from the quoted price, share count and announced subscription price.

The calculation illustrates potential upside rather than predicting a stock price. It assumes subscribers are paying throughout the year and does not model discounts, partner shares of revenue, cash, liabilities, costs or additional shares. Sekur’s financing needs and future dilution matter to the eventual per-share result. Still, the exercise shows why a signed partner, the SekurOne release and the first material premium sales could draw attention to a company valued at approximately US$6.3 million at the September 25 close.

The milestones to follow are close together: confirmation and terms of the Angolan partnership, progress on local onboarding, SekurOne’s October commercial rollout and subsequent disclosures of paid users or contract revenue. Each one would help investors measure how the company’s product development and international relationships are converting into business.

Sekur has now put a visible piece of its Angola strategy in place. If the company follows its Portuguese launch with a productive local partnership and recurring customer sales, Angola could become a meaningful new growth channel. Combined with SekurOne’s premium pricing and opportunities in other markets, that gives SWISF a route to revenue growth from a small starting valuation.

This article is for information and education only, not investment advice or a recommendation to buy or sell securities. The author may hold or trade SWISF. Sekur is a speculative, potentially illiquid microcap with operating losses and execution, financing and dilution risks. The subscriber and valuation scenarios are illustrative assumptions, not company forecasts or price targets. Readers should review the company’s filings and make their own investment decisions.

LifeQuest World Corp (OTCID: LQWC) Tuesday September 29, 2026 Blog

A UN University report released in January 2026 gave the world a stark new vocabulary for its water problems: "global water bankruptcy." The report found that nearly three in four people now live in water-insecure or critically water-insecure countries, that roughly four billion people face severe water scarcity for at least one month each year, and that more than half of the world's large lakes have shrunk since the early 1990s. "For much of the world, 'normal' is gone," said Kaveh Madani, director of the UN University Institute for Water, Environment and Health, in comments accompanying the report (UN News). Wastewater — how it's treated, reused, and kept out of already-stressed water bodies — sits at the center of that math.

Europe is responding with regulation. The recast EU Urban Wastewater Treatment Directive, which entered into force in early 2025 with phased compliance obligations running out to 2027 and beyond, dramatically widens the net: coverage now extends down to agglomerations of just 1,000 population equivalent, versus the much larger thresholds under the old rules (European Commission). That change pulls thousands of small towns, villages, and seasonal-tourism destinations across the EU into formal treatment obligations for the first time, alongside tighter nutrient and micropollutant limits and a new emphasis on water reuse and circularity.

That's a genuinely hard problem for conventional infrastructure. Centralized sewer networks and activated-sludge plants are expensive to extend to small, scattered populations, and package plants generally need to run near 80% of design capacity to perform reliably — a poor fit for a Mediterranean village whose population might triple every July and August. Oversize the plant for peak season and it underperforms (and still produces sludge to haul away) the other nine months of the year.

This is precisely the gap BioPipe Global's in-pipe technology was built for. Wastewater flows horizontally through modular pipe segments colonized by naturally occurring bacteria; passive aeration replaces energy-hungry blowers, no chemicals are dosed, and because the biological process consumes the organic solids in place, there's no sludge stream to collect, truck, and dispose of. Critically, the modules keep working efficiently across a wide load range — down to roughly 10% of rated capacity — so a system sized for August tourist crowds doesn't fail in April.

BioPipe's 300 m³/day project in Crete, Greece, announced in December 2025, is a live example of exactly this dynamic. "This 300 m³/day project in Crete represents a meaningful step forward in our European expansion strategy," said Robert Kaufmann, Director at BioPipe Global, noting that seasonal tourism surges there strain aging sewer networks in ways decentralized, rapidly deployable systems are well suited to address. The Crete plant is designed to meet stringent EU effluent standards — BOD below 10 mg/L, COD below 30 mg/L, and TSS below 10 mg/L — while producing near-zero odor, noise, and sludge. It followed BioPipe's earlier entry into Spain with a 10 m³/day system, giving the company two footholds in exactly the EU member states now facing the recast directive's expanded small-agglomeration requirements.

About LifeQuest World Corp. LifeQuest World Corp. (OTCID: LQWC) is a global technology company focused on low-cost, low-maintenance, eco-friendly decentralized wastewater treatment and solid waste compaction and recycling solutions, delivered through subsidiaries including BioPipe Global and Compaction and Recycling Equipment Inc. (CARE). Learn more at https://www.lifequestcorp.com.

This post contains forward-looking statements within the meaning of applicable securities laws, including statements regarding market opportunity, regulatory trends, and business strategy. Actual results may differ materially due to risks and uncertainties described in LifeQuest World Corp.'s filings. This content is for informational purposes only and does not constitute investment advice or an offer to buy or sell any security.

Hey guys, I posted about this settlement before, but since you can now submit an application, I decided to share it again with a little FAQ.

So here's all I know about this agreement:

Maison Solutions was accused of failing to disclose related-party dealings, prior allegations involving its CEO and related entities, and other risks tied to its IPO disclosures. After a December 2023 Hindenburg report raised these issues, $MSS fell 83.6%, and investors filed a lawsuit.

Now the company has reached a tentative settlement with investors to resolve the claims. The settlement terms are still being finalized, but you can submit an application now, which will be processed once claims filing opens.

Who can claim this settlement?
If you bought $MSS shares in 2023, you may be eligible.

Do I need to sell/lose my shares to get this settlement?
You don't need to still hold the shares. If you bought during the class period and suffered a qualifying loss, you may be eligible to participate.

Can I file a claim?
Yes, you can submit an application now. It will be processed once claims filing opens, check if you're eligible and file a claim here.

How long does the payout process take?
It typically takes 4 to 9 months after the claim deadline for payouts to be processed, depending on the court and settlement administration.

Hope this info helps

Alright regards. From the guy who brought you LASE last time, 3x the money when i post and gots hundreds of thank you. Now i bring you another sleeper. 

Invivyd $IVVD is a fun one. It's a small biotech company with real revenue, a product on a regulatory timer, and a Phase 3 readout that could land any day now. There's an independent paper on VYD2311, a closer look at the short side, and a sharp Stocktwits read on timing. If you are burned by many craps pennystock that got posted here, pay attention to this one.

Where things stand

The stock was around $0.90 on Thursday, down from $1.02 earlier in the week, which puts the market cap at roughly $260M by my math.

Invivyd ended Q2 with $160.1 million in cash, which management expects to carry it through the DECLARATION readout and launch prep. Burn runs near $40M a quarter, so figure roughly $120M today and about three quarters of runway.

The big structural issue: PEMGARDA's emergency use authorization now ends June 29, 2027. That's essentially all of Invivyd's current revenue. So what you're really buying is an option on VYD2311 replacing it.

The trial

DECLARATION is randomized, triple-blind and placebo-controlled, testing single or monthly intramuscular doses against placebo, with prevention of symptomatic COVID at 3 months as the primary endpoint. It was upsized by about 500 subjects to strengthen statistical power.

Safety has looked clean so far. After reviewing unblinded safety data, the independent monitoring committee recommended cutting post-dose monitoring from two hours to 30 minutes.

There's a second readout in the wings too. LIBERTY, roughly 210 participants comparing VYD2311 with an mRNA vaccine, may report alongside DECLARATION.

The September 1 twist

When Chairman Marc Elia became CEO on September 1, the company also laid out two paths for topline. It can fully unblind and file for traditional approval. Or it can partially unblind, keeping clinical events blinded, and file for Accelerated Approval based on antiviral activity and safety, with a confirmatory cohort afterward.

That's a smart fallback if the trial comes up short on statistical power. It also tells you management sees that risk as real. If the headline says "partially unblinded," expect the market to treat it like a miss, whatever the rest of the release says.

The new JCI Insight paper

This one is genuinely good news. It comes from David Ho's lab at Columbia, and none of the authors hold equity in, receive payments from, or consult for Invivyd.

The findings are strong. VYD2311 was roughly 27 to 124 times more potent than pemivibart against JN.1, XFG, BA.3.2.2 and NB.1.8.1, covering today's dominant variants and the very different newcomer BA.3.2.2. The dosing math works too. Phase 1/2 doses kept serum levels above 10 μg/mL at 90 days, while the toughest variant, NB.1.8.1, needed only about 1.05 μg/mL for 90% neutralization. That's roughly a 10x cushion.

The caveats are real though. The lab tested research-grade antibody it made itself, in pseudovirus assays, and the PK conclusion depends on confirmation that VYD2311 behaves like its parent molecule. Blood levels also aren't the same as protection in the nose, where infection starts. And the paper says nothing about whether DECLARATION racked up enough COVID cases to prove anything, which remains the main risk. It's also not fresh: it first appeared as an in-press preview on August 11.

Where it really helps is Plan B. An independent, peer-reviewed potency case is exactly what an Accelerated Approval filing on antiviral activity would lean on. One twist: the same paper raises concerns about PEMGARDA's continued efficacy against newer variants. Great for the VYD2311 story, less great for today's revenue.

Probability and rerating

With the paper in hand, I'd put a clean, statistically significant win at roughly 50–60%, and some viable BLA path at about 80%. Mapping outcomes from ~$0.90, with prices adjusted for the raise that follows almost any result:

Weighted, that lands comfortably above $0.90 on my numbers. But three of the four rows are flat or down, and everything hangs on that top probability, which nobody outside the company actually knows. One row pays; the rest cost.

Short squeeze potential

The short data tells a pretty clear story: there's real fuel here, but nobody's feeling the heat yet.

The fuel; About 14.33% of the float is sold short, roughly 29.8M shares. That's meaningful, though still below the 20–30% zone where the famous squeezes usually start. It also implies a float of around 208M shares, so this isn't a tiny-float rocket like TOPS or FBGL.

The standout number is days to cover at 16.19. At normal volume, shorts would need more than three weeks to get out, so a sudden volume spike on good news could send a lot of them for the exit at once.

The pressure, and this is where the setup falls short. The borrow fee is only 0.41–0.55%, so staying short costs almost nothing. Genuine squeeze setups tend to show fees in the double or even triple digits.

Borrow availability is also rising, from 5.9M to 6.5M shares, so there's plenty of stock for new shorts to reload into any spike. In a real squeeze, that number drains toward zero.

The 55–75% off-exchange short volume looks dramatic, but it's mostly market makers shorting to fill buy orders and closing quickly. I'd treat it as noise.

The company's side. Invivyd has a live ATM, and an offering is likely (may or may not) right after good data. That hands shorts even more shares to cover into.

On a clean DECLARATION win, covering from that high days-to-cover should add real fuel to the opening pop. Without tight borrow, though, expect the move to fade as new shorts and fresh supply step in, rather than a multi-day squeeze. On anything less than a clean win, the shorts get paid.

When does the data drop?

Stocktwits user ItsOkImANurse put together a really useful read on timing (quoted as posted, minus the Stocktwits ticker card):

"for biotech topline clinical data, Monday through Thursday is the normal zone, and Tuesday–Thursday tends to feel especially common. Friday releases happen, but companies generally avoid dropping major market-moving data late Friday unless timing dictates it.

For IVVD specifically, their history is actually pretty useful:

·       Monday: Dec. 18, 2023 — positive CANOPY Phase 3 results; Feb. 3, 2025 — positive VYD2311 Phase 1/2 data.

·       Tuesday: Nov. 12, 2024 — CANOPY clinical data/preprints; May 27, 2025 — CANOPY publication/data; Feb. 24, 2026 — new clinical analysis.

·       Thursday: June 26, 2025 — full VYD2311 Phase 1/2 clinical data, released at 7:01 AM ET.

·       Friday: March 22, 2024 — interim CANOPY exploratory data, so they clearly will use Friday when necessary.

Release?

Tomorrow Friday: possible, but not my favorite

Monday Sept. 28: very plausible

Tuesday Sept. 29: probably my favorite

Wednesday Sept. 30: extremely plausible because it’s literally the final day of Q3

Solid logic, and it lines up with the company's own plan. Management said it will host an investor call once the study wraps instead of doing a Q2 earnings call, so expect a premarket release with a call attached. His 7:01 AM ET example works out to 11:01 UTC. He posted on Thursday, so his "tomorrow Friday" is today.

If September 30 passes with nothing, that's information too. Slipping past "late Q3" would make the market nervous, especially with a two-path decision in play"

Last word

IVVD is a true sleeper gem in this biotech space. Granted biotech is hit and miss but when it hit it hit hard. And I believe IVVD is one of them. BTIG and Cantor rate them as buy with target at $10. Institutional holder is at 90% more.

Shoutout to u/justinrosser who introduced me to this stock.

May God (or whatever deity you believe in or not) help us all.

Lets goooo

A US$300-per-month secure-communications platform, government procurement access and a remarkably low subscriber target give this cybersecurity microcap meaningful operating leverage.

Sekur Private Data Ltd. (OTCQB: SWISF; CSE: SKUR) may be entering its most important commercial phase. At an estimated US$8.5 million market capitalization, investors are paying little for its government access, premium launch and potential path to profitability.

• Sekur is replacing low-priced consumer accounts with a US$300-per-month platform designed for governments, defense organizations and senior executives.
• Management estimates that only about 200 SekurOne subscribers could bring the company to profitability, highlighting the operating leverage of its premium model.
• Cybersecurity leaders carry market values from US$18 billion to more than US$300 billion, leaving Sekur considerable rerating room if it converts its pipeline into recurring revenue.

What Sekur Sells

Sekur sells encrypted email, messaging and VPN products. Its new flagship, SekurOne, combines voice, video, email, messaging and VPN services on its proprietary HeliX architecture. The company says its Swiss-hosted infrastructure avoids Big Tech cloud platforms and data mining, creating a differentiated privacy proposition.

SekurOne is expected on iOS and the web in early October 2026 at US$300 per month, with Android in November and video by year-end. An i3ICS GSA Multiple Award Schedule also gives U.S. agencies an established purchasing route.

Why Secure Communications Is Strategic

Cybersecurity is becoming basic infrastructure. MarketsandMarkets expects the market to grow from US$227.6 billion in 2025 to US$351.9 billion in 2030. The FBI recorded more than 1 million cybercrime complaints and US$20.9 billion of reported losses in 2025, including about US$3.0 billion from business email compromise.

The need is visible. Attackers accessed U.S. Treasury workstations in 2024, a U.K. military payroll breach exposed personnel information, and Costa Rica declared a national emergency after ransomware disrupted ministries. MGM Resorts estimated a roughly US$100 million profit hit from its 2023 attack.

Sekur does not need to replace broad security platforms. It can protect the sensitive communications layer used by officials and executives.

The 200-Subscriber Equation

Management estimates that 200 SekurOne users could make the company profitable within six months of launch. At US$300 per month, the arithmetic is simple:

This scenario assumes full pricing and excludes discounts, commissions and dilution.

In the first half, Sekur reported C$185,828 of revenue, C$1.53 million in cash and a C$2.18 million net loss. About C$1.28 million of the loss involved share-based compensation and shares for services. These figures precede SekurOne’s premium launch, making the coming quarters more relevant to the new model.

Sekur does not require mass-market adoption. One government deployment or several enterprise accounts could cover a meaningful portion of the target.

How Sekur Compares With Cybersecurity Leaders

Sekur’s tiny size creates its asymmetry. These are strategic benchmarks, not direct like-for-like competitors, but they show the value markets assign to recurring-revenue security platforms.

Market data are approximate through September 16–17, 2026. Sekur’s weaker performance leaves expectations low and creates room for reassessment if contracts validate the strategy.

Sekur need not approach multibillion-dollar status. US$50 million would equal 5.9 times its current value and US$100 million would equal 11.8 times, yet remain below 1% of Gen Digital’s capitalization. These illustrations require substantial commercial execution and are not forecasts.

The sector’s history shows that Sekur is not structurally confined to microcap status. Repeated government and enterprise wins could move it through progressively higher valuation tiers.

Bottom Line

Sekur combines a strategic market, premium recurring pricing, government access and a low stated threshold for profitability. At roughly US$0.0328 per share and US$8.5 million in market value, little commercial success appears priced in. Converting its government positioning into paying customers could therefore produce a meaningful rerating.

Disclaimer

• This article is for informational and educational purposes only. It is not investment advice or a recommendation to buy or sell securities.
• The author may hold or trade shares in SWISF or other securities mentioned without notice.
• SWISF is a speculative and potentially illiquid microcap. Investors can lose their entire investment and should independently verify company claims, filings and market data.

Merge with Findings

A bit about Findings: Founded in 2019, it's a provider of advanced solutions for managing cyber risks and information security in supply chains (Supply Chain Cyber ​​Risk) using artificial intelligence agents.

Hey guys, I posted about this settlement before, but since they’re accepting late claims, I decided to share it again with a little FAQ.

So here's all I know about this agreement:

F45 Training Holdings was accused of misleading investors about its franchise-growth and revenue model, including how it generated upfront franchise payments. After the company cut its guidance, reduced opening plans, and disclosed that a $250M credit line would not be available, $FXLV fell more than 60% in one day, and investors filed a lawsuit.

Now the company has agreed to settle $10.5M with investors for their losses.

Who can claim this settlement?
If you bought $FXLV shares between 2021 and 2023, you may be eligible. You don’t need to still hold the shares to claim; past losses may count. Late claims are currently being considered, subject to approval.

Do I need to sell/lose my shares to get this settlement?
No. You don’t need to still own your $FXLV shares. If your transactions meet the settlement requirements, you may be eligible even if you already sold them.

I missed the deadline. Is it too late? 
No, you may still be able to file a late claim, but acceptance depends on final approval by the court. Check if you're eligible and file your claim here 

How long does the payout process take?
It typically takes 4 to 9 months after the claim deadline for payouts to be processed, depending on the court and settlement administration.

Hope this info helps

The last time $SPRU broke MA50 on the daily (attached) it climbed from ~$1.50 to $6.75.
I'm calling attention to it because it's reflecting that same pattern right now and is getting some really interesting price action.

Here are some background specs:
Spruce Power owns and operates U.S. residential solar assets, generating recurring revenue from long term contracts.

$35M market cap, ~16M float

$81.5M total cash + restricted cash, or $4.24/share, this makes roughly 125 months of runway based on current burn rate.

$802M gross solar portfolio value

Q2 swung from a $3M loss to $3.3M net income

Record Operating EBITDA of $26.5M

As of yet I don't see any news to support the move thus far. There are some potential, underlying catalysts that could be in play, including:

Continued solar sector momentum
Lot's of solar buzz, Elon is vocally promoting solar. Could well become a theme this fall/winter.

Strategic solar portfolio acquisitions
These guys are in aggressive expansion mode and any acquisitions could be meaningful catalysts.

Potential share buybacks with $42M remaining authorized
Not just speculation, the structure is already in place. This would be a golden ticket.

Continued profitability + EBITDA growth
Coming off positive earnings performance, any follow-on or preliminary updates would be net-positive for share price.

I'm looking at this as a potential near-term breakout trade as well as a swing. Also looking at other beaten down solar for swings as they typically do well every Oct/Nov.

I'm adding charts but for respectable TA I'll need a bit more time to crank it out. Birdseye view, everything looks very positive. Will wait until I can drill down to update with more specifics. Or, ofc, feel free to jump in with your own readings.

Sorry for the brevity, just wanted to offer this up for your analysis.

Thanks all.

https://reglobal.org/the-us-solar-market-insight-seia-report/

$SKUR timeline from here:

Late August: Encrypted video + video conferencing
Before Sept. 30: Full SekurOne platform
After that: Broader commercial sales

What do you think comes first once the full platform is live: customer growth or a government contract?

Paid content. DYODD.